Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLNCF) Short-term Investments (2019 - 2025)

Historic Short-term Investments for Silence Therapeutics (SLNCF) over the last 5 years, with Q3 2025 value amounting to $20.2 million.

  • Silence Therapeutics' Short-term Investments changed N/A to $20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year change of. This contributed to the annual value of $26.0 million for FY2024, which is 2966.19% down from last year.
  • Latest data reveals that Silence Therapeutics reported Short-term Investments of $20.2 million as of Q3 2025.
  • In the past 5 years, Silence Therapeutics' Short-term Investments registered a high of $72.4 million during Q2 2025, and its lowest value of $20.2 million during Q3 2025.
  • For the 3-year period, Silence Therapeutics' Short-term Investments averaged around $45.4 million, with its median value being $37.0 million (2023).
  • Over the last 5 years, Silence Therapeutics' Short-term Investments had its largest YoY gain of 2966.19% in 2024, and its largest YoY loss of 2966.19% in 2024.
  • Silence Therapeutics' Short-term Investments (Quarter) stood at $37.0 million in 2023, then decreased by 29.66% to $26.0 million in 2024, then decreased by 22.47% to $20.2 million in 2025.
  • Its Short-term Investments stands at $20.2 million for Q3 2025, versus $72.4 million for Q2 2025 and $71.6 million for Q1 2025.